

Program

Welcome & Introduction

Prof. David Lillicrap, Kingston, ON, Canada

Treating With Gene Therapy & Shared Decision-making: A Collaborative Expedition **Through Uncertainties**

Prof. Margareth Ozelo, Campinas, SP, Brazil

Liver Health and Corticosteroid Use

Prof. Paolo Angeli, Padua, Italy

Long-term Safety & Follow-up in Gene Therapy: What Do We Know?

Prof. David Lillicrap, Kingston, ON, Canada

More Than Just Numbers: What Does Gene Therapy Really Mean for the Patient?

Prof. Barbara A. Konkle, Seattle, WA, USA

Closing Remarks

Prof. David Lillicrap, Kingston, ON, Canada

Q&A

Faculty & audience

Faculty



Prof. David Lillicrap

Queen's University, Kingston, ON, Canada

David Lillicrap is Professor in the Department of Pathology and Molecular Medicine at Queen's University in Kingston, ON, Canada. His main research interests are focused on the immune response to factor VIII in Hemophilia A, the development and evaluation of novel therapies for Hemophilia A and the pathobiology of von Willebrand factor. He is a past-Chair of the WFH Research Committee and member of the Medical Advisory Board of the WFH. He is a pastmember of Council of ISTH, and is currently one of the two Editors-in-Chief of the Journal of Thrombosis and Haemostasis.



Prof. Margareth Ozelo

University of Campinas, Campinas, SP, Brazil

Margareth Ozelo is Professor at the Internal Medicine Department and Director of the Hematology Division at the University of Campinas (UNICAMP) in Campinas, São Paulo, Brazil. She is involved in several research projects including gene therapy for Hemophilia, risk factors for inhibitor development, immune tolerance induction and the management of musculoskeletal complications of Hemophilia and inherited platelet disorders. Prof. Ozelo is also Director of the WFH International Hemophilia Training Center from Hemocentro UNICAMP.



Prof. Paolo Angeli

University of Padua, Padua, Italy

Paolo Angeli is Professor of Internal Medicine and Head of the Unit of Internal Medicine and Hepatology of the University of Padua, Italy. He is also Chair of the EASL-Clif Consortium and Editor-in-Chief of the Journal of Hepatology. Prof. Angeli has an interest in the pathophysiology and treatment of liver failure and liver transplantation. He has also contributed to guidelines/ papers on the management of patients with decompensated cirrhosis.



Prof. Barbara A. Konkle

University of Washington School of Medicine, Seattle, WA, USA

Barbara Konkle is Professor of Medicine in Hematology at the University of Washington in Seattle, WA, USA. She currently serves as the Chair of the Steering Committee for the WFH Gene Therapy Registry. Prof. Konkle has a long-standing interest in the genetics of bleeding disorders and recently led the 'My Life Our Future' project which genotyped over 11,000 patients and potential carriers of Hemophilia. Since 2001, she has also been participating in clinical trials of gene therapy for Hemophilia.



